| pubmed-article:2452254 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:2452254 | lifeskim:mentions | umls-concept:C0001175 | lld:lifeskim |
| pubmed-article:2452254 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:2452254 | lifeskim:mentions | umls-concept:C0087111 | lld:lifeskim |
| pubmed-article:2452254 | lifeskim:mentions | umls-concept:C1882534 | lld:lifeskim |
| pubmed-article:2452254 | lifeskim:mentions | umls-concept:C0001857 | lld:lifeskim |
| pubmed-article:2452254 | lifeskim:mentions | umls-concept:C0871161 | lld:lifeskim |
| pubmed-article:2452254 | lifeskim:mentions | umls-concept:C0795760 | lld:lifeskim |
| pubmed-article:2452254 | lifeskim:mentions | umls-concept:C0449435 | lld:lifeskim |
| pubmed-article:2452254 | lifeskim:mentions | umls-concept:C0332167 | lld:lifeskim |
| pubmed-article:2452254 | pubmed:issue | 4 | lld:pubmed |
| pubmed-article:2452254 | pubmed:dateCreated | 1988-6-2 | lld:pubmed |
| pubmed-article:2452254 | pubmed:abstractText | We have evaluated the immunomodulatory effects of isoprinosine in a double blind randomized clinical study on 63 immunosuppressed male homosexuals with persistent generalized lymphadenopathy (PGL) or ARC. The subjects received either placebo or isoprinosine at 1 or 3 g/day for 28 days. All subjects were monitored for performance for a one year period. In the 3 g/day treatment group clinical improvement was reported by 52% of the patients in contrast to 15% in the placebo group. Patients receiving 3 g/day isoprinosine showed significant increase in NK cells, a major subset of which bears the Leu 7 surface antigen, and in NK cell function as early as at the termination of treatment. This normalized NK cell property was still evident 5 months after cessation of therapy. Total T lymphocytes and T helper cells also increased in this group and a concomitant reduction was observed in activated T lymphocytes (HLA-DR+). As a direct result of the therapy an increase was found in the Th regulatory (Leu 3+ Leu 8+) cell population resulting in normalization of Th inducer/Th regulatory cell ratio. A concomitant reduction to normal range occurred in Ts effector (Leu 2+ Leu 8-) and functionally activated Ts (Leu 2+ HLA-DR+) cell populations. The kinetics of these effects suggest that isoprinosine stimulates the production of precursor lymphocytes and initiates a process of cell differentiation capable of producing long-term restoration of host immunity. | lld:pubmed |
| pubmed-article:2452254 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2452254 | pubmed:language | eng | lld:pubmed |
| pubmed-article:2452254 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2452254 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:2452254 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2452254 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2452254 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2452254 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:2452254 | pubmed:month | Dec | lld:pubmed |
| pubmed-article:2452254 | pubmed:issn | 0141-2760 | lld:pubmed |
| pubmed-article:2452254 | pubmed:author | pubmed-author:BekesiJ GJG | lld:pubmed |
| pubmed-article:2452254 | pubmed:author | pubmed-author:RobozJ PJP | lld:pubmed |
| pubmed-article:2452254 | pubmed:author | pubmed-author:WallaceJ IJI | lld:pubmed |
| pubmed-article:2452254 | pubmed:author | pubmed-author:TsangP HPH | lld:pubmed |
| pubmed-article:2452254 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:2452254 | pubmed:volume | 24 | lld:pubmed |
| pubmed-article:2452254 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:2452254 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:2452254 | pubmed:pagination | 155-61 | lld:pubmed |
| pubmed-article:2452254 | pubmed:dateRevised | 2007-11-15 | lld:pubmed |
| pubmed-article:2452254 | pubmed:meshHeading | pubmed-meshheading:2452254-... | lld:pubmed |
| pubmed-article:2452254 | pubmed:meshHeading | pubmed-meshheading:2452254-... | lld:pubmed |
| pubmed-article:2452254 | pubmed:meshHeading | pubmed-meshheading:2452254-... | lld:pubmed |
| pubmed-article:2452254 | pubmed:meshHeading | pubmed-meshheading:2452254-... | lld:pubmed |
| pubmed-article:2452254 | pubmed:meshHeading | pubmed-meshheading:2452254-... | lld:pubmed |
| pubmed-article:2452254 | pubmed:meshHeading | pubmed-meshheading:2452254-... | lld:pubmed |
| pubmed-article:2452254 | pubmed:meshHeading | pubmed-meshheading:2452254-... | lld:pubmed |
| pubmed-article:2452254 | pubmed:meshHeading | pubmed-meshheading:2452254-... | lld:pubmed |
| pubmed-article:2452254 | pubmed:meshHeading | pubmed-meshheading:2452254-... | lld:pubmed |
| pubmed-article:2452254 | pubmed:meshHeading | pubmed-meshheading:2452254-... | lld:pubmed |
| pubmed-article:2452254 | pubmed:meshHeading | pubmed-meshheading:2452254-... | lld:pubmed |
| pubmed-article:2452254 | pubmed:meshHeading | pubmed-meshheading:2452254-... | lld:pubmed |
| pubmed-article:2452254 | pubmed:meshHeading | pubmed-meshheading:2452254-... | lld:pubmed |
| pubmed-article:2452254 | pubmed:meshHeading | pubmed-meshheading:2452254-... | lld:pubmed |
| pubmed-article:2452254 | pubmed:meshHeading | pubmed-meshheading:2452254-... | lld:pubmed |
| pubmed-article:2452254 | pubmed:year | 1987 | lld:pubmed |
| pubmed-article:2452254 | pubmed:articleTitle | Immunorestorative properties of isoprinosine in the treatment of patients at high risk of developing ARC or AIDS. | lld:pubmed |
| pubmed-article:2452254 | pubmed:affiliation | Department of Neoplastic Diseases, Mount Sinai School of Medicine and Hospital, City University, New York, N.Y. 10029. | lld:pubmed |
| pubmed-article:2452254 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:2452254 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:2452254 | pubmed:publicationType | Research Support, U.S. Gov't, P.H.S. | lld:pubmed |
| pubmed-article:2452254 | pubmed:publicationType | Randomized Controlled Trial | lld:pubmed |
| pubmed-article:2452254 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2452254 | lld:pubmed |
